HONG KONG – South Korean biopharmaceutical giant Celltrion Group, of Incheon, and Korea Development Bank (KDB), a wholly state-owned policy development bank, have agreed to run a fund worth KRW220 billion (US$184 million) to grow venture companies in Korea's bio-health care sector.